Institute For Neurodegenerative Disorders
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.indd.org
Clinical Trials
45
Active:4
Completed:29
Trial Phases
5 Phases
Early Phase 1:4
Phase 1:22
Phase 2:11
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (56.4%)Phase 2
11 (28.2%)Early Phase 1
4 (10.3%)Not Applicable
1 (2.6%)Phase 4
1 (2.6%)Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 19
- Registration Number
- NCT01767493
- Locations
- 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 16
- Registration Number
- NCT01462708
- Locations
- 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 4
- Registration Number
- NCT01461109
- Locations
- 🇺🇸
Institute_Neurodegenerative_Disorders, New Haven, Connecticut, United States
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 19
- Registration Number
- NCT01461083
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 5
- Registration Number
- NCT01268020
- Locations
- 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found